PPT-LPV-RTV + 3TC vs. LPV-RTV + 2 NRTIs in

Virologically Suppressed OLE Trial LPVRTV 3TC vs LPV RTV 2 NRTIs in Virologically Suppressed OLE Study Design Source Arribas JR et al Lancet Infect Dis 201515 78592. r. + 3TC. OLE . Study. LPV/. r. bid + 3TC or FTC . qd. + NRTI. N =. 127. N =. 123. LPV/. r. bid + 3TC/FTC . qd. Design. Randomisation*. 1: 1. Open-label. Objective. Primary Endpoint :. proportion without treatment failure at W48 . (with perspectives from well-resourced and resource-limited settings). Gareth Tudor-Williams. Imperial College London. UK. Where would you prefer to be right now?. Langkawi resort?. Attending a workshop?. STRIIVING . Study. Design. Endpoints. Primary: proportion of patients maintaining HIV RNA < 50 c/mL at W48 . (ITT-E, snapshot) ; non-inferiority if lower margin of the two-sided 95% CI . for the difference = - 10%, 90% power . 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Compared With Lopinavir/Ritonavir (LPV/RTV) Plus . 2 NRTIs in Second-Line Treatment: Interim Data From the DAWNING Study. Michael Aboud,. 1. Richard Kaplan,. Martina Penazzato MD, PhD. Paediatric lead, HIV Department. World Health Organization, Geneva. Background. 1.8 million children were estimated to live with HIV in 2017. In 2017, only 51 % of HIV-exposed infants received EID (by 2mo). Action. Improving Access to Optimized Treatment . for Children . Living with HIV. Melbourne, 22 July 2014. Marc Lallemant & Janice Lee. DNDi. mlallemant@dndi.org. Malaria. Leishmaniasis. implementation of Dolutegravir. Meireles MV. , Pascom ARP, Perini F, Rick F, Benzaken A. . Ministry of Health of Brazil, Department of STI, AIDS and Viral Hepatitis. Acknowledgements. No. . conflicts of interest. Switch to LPV/r + RAL KITE Study KITE Study: switch to LPV/r + RAL Design Age ≥ 18 years HIV+ No previous virologi c failure to PI/r-based ART HIV-1 RNA < 50 c/ml On stable (≥ 6 months) 2 NRTI + 3rd agent nd. 90: Child Friendly Formulations . Victor Musiime, . MBChB. , MMED, PhD. Senior Lecturer, . Makerere. University. Investigator, Joint Clinical Research Centre. Kampala, Uganda. Disclosure statement. DUAL-GESIDA. Dual Maintenance ART with RTV-Boosted Darunavir + . Lamivudine. DUAL . GESIDA: . Study Design. Source: . Pulido. . F, . et al. . Clin Infect . Dis..  . 2017;65:2112-8.. DRV + RTV + 3TC. FLAMINGO. Dolutegravir + 2 NRTIs versus Darunavir + RTV + 2 NRTIs . FLAMINGO: Study Design. Source: . Clotet. B, et al. . Lancet. 2014;383:2222-31. . Dolutegravir + . TDF-FTC or ABC-3TC. (n = 242). Darunavir + Ritonavir + . STEAL. Switch NRTIs to Tenofovir DF-Emtricitabine or Abacavir-Lamivudine. STEAL: Study Design. Source: . Martin A, et al. . Clin. Infect . Dis. 2009;49:1591. -1601. .. Study Design: STEAL. Background. ACTG 5202. EFV versus ATV/r, both with ABC-3TC or TDF-FTC. ACTG 5202: Study Design. Source: . Daar. ES, et al. . Ann Intern Med. 2011;154:445-56. . EFV + ABC-3TC. (n = 465). ATV + RTV + ABC-3TC. (n = 463). HIV-NAT . 017. SQV and . LPV-RTV . in Treatment-Experienced Children . HIV-NAT . 017: . Study . Design. Source: . Kosalaraksa. P, et al. . Pediatr. Infect Dis J. . 2008;27:. 623-8. . SQV + LPV-RTV +/- 3TC.